![CIRRUS 6000 CIRRUS 6000]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.100.56.file/ga_cropped_1.jpg","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.360.203.file/ga_cropped_1.jpg","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.768.432.file/ga_cropped_1.jpg","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.1024.576.file/ga_cropped_1.jpg","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.1280.720.file/ga_cropped_1.jpg","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original.image_file.1440.810.file/ga_cropped_1.jpg","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/ga_cropped_1.jpg/_jcr_content/renditions/original./ga_cropped_1.jpg"})
CIRRUS OCT
Toolkit AMD e Atrofia Geografica
Offri ai tuoi pazienti l’opportunità di accedere alla nuova era del trattamento e della cura dell’AMD con l’Advanced RPE Analysis e ZEISS AngioPlex, il toolkit per AMD e atrofia geografica di ZEISS CIRRUS.
La degenerazione maculare legata all’età (AMD) è la causa principale di perdita grave e irreversibile della vista nelle persone di età superiore ai 60 anni e sta crescendo ad un ritmo allarmante in tutto il mondo. I tuoi pazienti potrebbero esserne a rischio. Si stima che nel 2020 erano 196 milioni le persone affette da AMD e che tale numero salirà a 288 milioni entro il 2040, ma il 25% delle AMD in ambito oculistico primario non viene diagnosticato.1,2 Si tratta di un aumento di oltre il 46%: 92 milioni di persone in più che potrebbero rischiare di perdere la vista, senza neanche saperlo. Possiamo aiutarli. Impara ad utilizzare Advanced RPE Analysis e AngioPlex® come toolkit per la diagnosi e il trattamento di pazienti affetti da AMD e atrofia geografica.
![]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.100.100.80,0,560,480.file/196-million.png","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.360.360.80,0,560,480.file/196-million.png","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/196-million.png","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/196-million.png","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/196-million.png","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/196-million.png","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/196-million.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/196-million.png"})
Si stima che nel 2020 erano 196 milioni le persone nel mondo affette da AMD.
![]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.100.100.23,0,428,405.file/affect-central-vision_lrg.jpg","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.360.360.23,0,428,405.file/affect-central-vision_lrg.jpg","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/affect-central-vision_lrg.jpg","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/affect-central-vision_lrg.jpg","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/affect-central-vision_lrg.jpg","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/affect-central-vision_lrg.jpg","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/affect-central-vision_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/affect-central-vision_lrg.jpg"})
L’AMD colpisce la visione centrale, altri 92 milioni di persone potrebbero essere a rischio di perdita della vista.
![]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.100.100.80,0,560,480.file/60-plus.png","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.360.360.80,0,560,480.file/60-plus.png","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/60-plus.png","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/60-plus.png","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/60-plus.png","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/60-plus.png","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/60-plus.png/_jcr_content/renditions/original.image_file.480.480.80,0,560,480.file/60-plus.png"})
Gli adulti di età superiore ai 60 anni sono più a rischio di sviluppare l’AMD.
![]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.100.100.23,0,428,405.file/risk-factors_lrg.jpg","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.360.360.23,0,428,405.file/risk-factors_lrg.jpg","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/risk-factors_lrg.jpg","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/risk-factors_lrg.jpg","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/risk-factors_lrg.jpg","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/risk-factors_lrg.jpg","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/risk-factors_lrg.jpg/_jcr_content/renditions/original.image_file.405.405.23,0,428,405.file/risk-factors_lrg.jpg"})
Il fumo, l’anamnesi familiare, una dieta non sana, l’inattività e l’esposizione alla luce solare sono alcuni dei fattori di rischio per lo sviluppo dell’AMD.
Una nuova era per l’atrofia geografica
Il ruolo dell’OCT
![Advanced RPE Analysis Advanced RPE Analysis]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.100.56.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.360.203.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.768.432.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.1024.576.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.1031.580.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.1031.580.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/article-1-advanced-rpe-analysis/figure2-rpe_analysis_selection16_9.jpg/_jcr_content/renditions/original.image_file.1031.580.1,0,1032,580.file/figure2-rpe_analysis_selection16_9.jpg"})
Advanced RPE Analysis
Misurazione quantitativa e confronto dei dati storici
L’Advanced RPE Analysis, disponibile per l’OCT ZEISS CIRRUS, è stata creata appositamente per aiutare i medici a gestire l’AMD non-neovascolare in tutte le sue forme.
![AngioPlex AngioPlex]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.100.56.0,130,1341,886.file/article_2_figure_2-octa_report.png","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.360.203.0,130,1341,886.file/article_2_figure_2-octa_report.png","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.768.432.0,130,1341,886.file/article_2_figure_2-octa_report.png","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.1024.576.0,130,1341,886.file/article_2_figure_2-octa_report.png","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.1280.720.0,130,1341,886.file/article_2_figure_2-octa_report.png","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.1341.754.0,130,1341,886.file/article_2_figure_2-octa_report.png","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_2_figure_2-octa_report.png/_jcr_content/renditions/original.image_file.1341.754.0,130,1341,886.file/article_2_figure_2-octa_report.png"})
AngioPlex
Importanza del rilevamento precoce della progressione
I sistemi di angiografia OCT (OCTA) come ZEISS CIRRUS AngioPlex®, continuano ad ampliare i confini dell’imaging oculare in modo che i medici possano offrire le migliori cure possibili a questi pazienti.
![Un modello di assistenza collaborativa Un modello di assistenza collaborativa]({"xsmall":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.100.56.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","small":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.360.203.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","medium":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.768.432.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","large":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.1024.576.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","xlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.1280.720.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","xxlarge":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.1440.810.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png","max":"https://www.zeiss.com/content/dam/med-hcp/reference-master/product-portfolio/oct-systems/cirrus-6000/images/article_3_table_1-amd_classification_table.png/_jcr_content/renditions/original.image_file.1920.1080.84,0,2157,1166.file/article_3_table_1-amd_classification_table.png"})
Un modello di assistenza collaborativa
Ottimizzazione dei risultati per i pazienti
L’OCT ZEISS CIRRUS con l’Advanced RPE Analysis e AngioPlex® può fornire la base su cui optometristi e oftalmologi possono rilevare e monitorare tutte le forme di AMD.
Download
Contattaci!
Servizi disponibili
-
1
Wong, Wan Ling, et al. “Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.” The Lancet Global Health 2.2 (2014): e106-e116
-
2
Neely DC, Bray KJ, Huisingh CE, et al. Prevalence of undiagnosed age-related macular degeneration in primary eye care. JAMA Ophthalmol. 2017;135(6):570-5